

## FABRIZIO VINANTE, MD

---

Associate Professor of Hematology at the University of Verona, Italy

Clinical management of leukemia, lymphoma and myeloma, Hematology Unit, University Hospital of Verona

Research on Cell Biology of Cancer, Department of Medicine, University of Verona

Former Visiting Associate at the Molecular Biology Laboratory, Derald H. Ruttenberg Cancer Center, Mount Sinai School of Medicine and The Rockefeller University, New York, NY

### PAPERS

1. Rigo A, Ferrarini I, Lorenzetto E, Darra E, Liparulo I, Bergamini C, Sissa C, Cavalieri E, Vinante F. BID and the  $\alpha$ -bisabolol-triggered cell death program: converging on mitochondria and lysosomes. *Cell Death Dis* 10:889,2019.
2. Ferrarini I, Rigo A, Zamò A, Vinante F. Classical Hodgkin lymphoma cells may promote an IL-17-enriched microenvironment. *Leuk Lymphoma* 60:3395-3405,2019.
3. Ferrarini I, Rigo A, Gandini A, Vinante F. West Nile Virus Encephalitis in Haematological Setting: Report of Two Cases and a Brief Review of the Literature. *Mediterr J Hematol Infect Dis* 11:e2019033,2019.
4. Ferrarini I, Rigo A, Montresor A, Laudanna C, Vinante F. Monocyte-to-macrophage switch reversibly impaired by Ibrutinib. *Oncotarget* 10:1943-1956,2019.
5. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. In replay to Schäfer et al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma. *Br J Haematol* 184:1052-1055,2019.
6. Montresor A, Toffali L, Rigo A, Ferrarini I, Vinante F, Laudanna C. CXR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase. *Oncotarget* 9:35123-35140,2018.
7. Rigo A, Ferrarini I, Innamorati G, Vinante F. A single amino acid substitution in CXCL12 confers functional selectivity at the beta-arrestin level. *Oncotarget* 9:28830-28841,2018.
8. Rigo A, Ferrarini I, Bonalumi A, Tecchio C, Montresor A, Laudanna C, Vinante F. Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol  $\alpha$ -bisabolol, a dual proapoptotic and antiautophagic agent. *Oncotarget* 9:25877-25890,2018.
9. Zoico E, Rizzatti V, Darra E, Budui SL, Franceschetti G, Vinante F, Pedrazzani C, Guglielmi A, De Manzoni G, Mazzali G, Rossi AP, Fantin F, Zamboni M. Morphological and Functional Changes in the Peritumoral Adipose Tissue of Colorectal Cancer Patients. *Obesity (Silver Spring)* 25: S87-S94,2017.
10. Russignan A, Spina C, Tamassia N, Cassaro A, Rigo A, Bagnato A, Rosanò L, Bonalumi A, Gottardi M, Zanatta L, Giacomazzi A, Scupoli MT, Tinelli M, Salvadori U, Mosna F, Zamò A, Cassatella MA, Vinante F, Tecchio C. Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma. *Br J Haematol* 178: 781-793,2017.
11. Mazzoni E, Pietrobon S, Bilancia M, Vinante F, Rigo A, Ferrarini I, D'Agostino A, Casali MV, Martini F, Tognon M. High prevalence of antibodies reacting to mimotopes of Simian virus 40 large T antigen, the oncoprotein, in serum samples of patients affected by non-Hodgkin lymphoma. *Cancer Immunol Immunother* 66: 1189-1198,2017

12. Rigo A, Vinante F. Flow cytometry analysis of receptor internalization/shedding. *Cytometry B Clin Cytom* 92: 291-298,2017.
13. Rigo A, Vinante F. The antineoplastic agent  $\alpha$ -bisabolol promotes cell death by inducing pores in mitochondria and lysosomes. *Apoptosis* 21: 917-927,2016.
14. Montresor A, Toffali L, Mirinda M, Rigo A, Vinante F, Laudanna C. JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia. *Oncotarget* 6:34245-34257,2015.
15. Caliò A, Zamò A, Ponzoni M, Zanolin ME, Ferreri AJ, Pedron S, Montagna L, Parolini C, Fraifeld VE, Wolfson M, Yanai H, Pizzolo G, Doglioni C, Vinante F, Chilosi M. Cellular senescence markers p16INK4a and p21CIP1/WAF are predictors of Hodgkin lymphoma outcome. *Clin Cancer Res* 21:5164-5172,2015
16. Tognon M, Luppi M, Corallini A, Taronna A, Barozzi P, Rotondo JC, Comar M, Casali MV, Bovenzi M, D'Agostino A, Vinante F, Rigo A, Ferrarini I, Barbanti-Brodano G, Martini F, Mazzoni E. Immunologic evidence of a strong association between non-Hodgkin lymphoma and simian virus 40. *Cancer* 121:2618-2626,2015.
17. Vinante F. Le Anemie. In *Core Curriculum Ematologia*, Mc Graw Hill, Milan, pages 43-83,2014.
18. Vinante F, Tomei P, Zaza G, Zamò A, Lupo A. Hairy cell leukemia in kidney transplantation: lesson from a rare disorder. *Exp Hematol Oncol* 2:22,2013.
19. Vinante F, Rigo A. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor in normal and neoplastic hematopoiesis. *Toxins (Basel)* 5:1180-1201, Review,2013
20. Bonifacio M, Rigo A, Guardalben E, Bergamini C, Cavalieri E, Fato R, Pizzolo G, Suzuki H, Vinante F.  $\alpha$ -bisabolol is an effective proapoptotic agent against BCR-ABL(+) cells in synergism with Imatinib and Nilotinib. *PLoS One* 7:e46674,2012
21. Rigo A, Gottardi M, Damiani E, Bonifacio M, Ferrarini I, Mauri P, Vinante F. CXCL12 and [N33A]CXCL12 in 5637 and HeLa cells: regulating HER1 phosphorylation via calmodulin/calcineurin. *PLoS One* 7:e34432,2012
22. Cavalieri E, Rigo A, Bonifacio M, de Prati AC, Guardalben E, Bergamini C, Fato R, Pizzolo G, Suzuki H, Vinante F. Pro-apoptotic activity of  $\alpha$ -bisabolol in preclinical models of primary human acute leukemia cells. *J Transl Med.* 9:45-50,2011
23. Della Peruta M, Martinelli G, Moratti E, Pintani D, Vezzalini M, Mafficini A, Grafone T, Iacobucci I, Soverini S, Murineddu M, Vinante F, Tecchio C, Piras G, Gabbas A, Monne M, Sorio C. Protein tyrosine phosphatase receptor type  $\{\gamma\}$  is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia. *Cancer Res* 70:8896-8906,2010
24. Rigo A, Gottardi M, Zamò A, Mauri P, Bonifacio M, Krampera M, Damiani E, Pizzolo G, Vinante F. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. *Mol Cancer* 9:273,2010
25. Montresor A, Bolomini-Vittori M, Simon SI, Rigo A, Vinante F, Laudanna C. Comparative analysis of normal versus CLL B-lymphocytes reveals patient-specific variability in signaling mechanisms controlling LFA-1 activation by chemokines. *Cancer Res* 69:9281-9290,2009
26. Scupoli MT, Donadelli M, Cioffi F, Rossi M, Perbellini O, Malpeli G, Corbioli S, Vinante F, Krampera M, Palmieri M, Scarpa A, Ariola C, Foà R, Pizzolo G. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways. *Haematologica* 93:524-532,2008
27. Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, Pizzolo G. Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. *Haematologica* 92:264-266,2007
28. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlaschi V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-gamma in the

- immunomodulatory activity of human bone marrow mesenchymal stem cells. *Stem Cells* 24:386-398,2006
29. Krampera M, Pasini A, Rigo A, Scupoli MT, Tecchio C, Malpeli G, Scarpa A, Dazzi F, Pizzolo G, Vinante F. HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. *Blood* 106:59-66,2005
  30. Scupoli MT, Vinante F, Krampera M, Vincenzi C, Nadali G, Zampieri F, Ritter MA, Eeren E, Santini F, Pizzolo G. Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. *Haematologica* 88:1229-1237,2003
  31. Vinante F. Growth and differentiation signalling in myeloma cells. *Haematologica* 88 (Suppl 14):33-34,2003
  32. Vinante F. Leucopenia e leucocitosi. In: "Crepaldi G, Baritussio A, Trattato di Medicina Interna, Volume II", Piccin Editore, Padova, pag 3037-3049,2003.
  33. Maserati E, Aprili F, Vinante F, Locatelli F, Amendola G, Zatterale A, Milone G, Minelli A, Bernardi F, Lo Curto F, Pasquali F. Trisomy 8 in myelodysplasia and acute leukemia is constitutional in 15-20% of cases. *Genes Chromosomes Cancer* 33:93-97,2002
  34. Vinante F, Rigo A, Scupoli MT, Pizzolo G. CD30 triggering by agonistic antibodies regulates CXCR4 expression and CXCL12 chemotactic activity in the cell line L540. *Blood* 99:52-60,2002
  35. Revoltella RP, Laricchia Robbio L, Moscato S, Vinante F, Fasciani A, Liberati AM, Reato G, Foa R. Naturally-occurring anti-G-CSF antibodies produced by human cord blood B-cell lines infected with Epstein-Barr virus. *Hematology J* 2:161-171,2001.
  36. Gerli R, Lunardi C, Vinante F, Bistoni O, Pizzolo G, Pitzalis C. Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for the Th1-driven diseases. *Trends Immunol* 22:72-77,2001
  37. Revoltella RP, Laricchia Robbio L, Liberati AM, Reato G, Foa R, Funaro A, Vinante F, Pizzolo G. Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. *Cell Immunol* 204:114-127,2000
  38. Bazzoni F, Gatto L, Lenzi L, Vinante F, Pizzolo G, Zanolin E, De Gironcoli M. Identification of novel polymorphisms in the human TNFR1 gene: distribution in acute leukemia patients and healthy individuals. *Immunogenetics* 51:159-163, 2000
  39. Krampera M, Antico A, Vinante F, Morosato L, Pizzolo G. Lymphocyte membrane antigen expression and intracellular cytokine patterns in an asymptomatic patient with persistently high serum levels of IgE. *Ann Allergy Asthma Immunol* 83:144-8,1999
  40. Vinante F, Rigo A, Cassatella M, Pizzolo G. Interleukin-8 in acute myeloid leukemia. *Blood (letter)* 93:1437, 1999
  41. Vinante F, Marchi M, Rigo A, Scapini P, Pizzolo G, Cassatella MA. Granulocyte-macrophage colony-stimulating factor induces expression of heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor and sensitivity to diphtheria toxin in human neutrophils. *Blood* 94:3169-77,1999
  42. Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G. Heparin binding epidermal growth factor-like growth factor (HB-EGF)/diphtheria toxin receptor expression by acute myeloid leukemia cells. *Blood* 93:1715-1723,1999
  43. Vinante F, Krampera M, Morosato L, Rigo A, Romagnani S, Pizzolo G. Peripheral T lymphocyte cytokine profile (IFN $\gamma$ , IL-2, IL-4) and CD30 expression/release during measles infection. *Haematologica* 84:683-9,1999
  44. Krampera M, Vinante F, Tavecchia L, Morosato L, Chilosi M, Romagnani S, Zanolin ME, Pizzolo G. Progressive polarization towards a T helper/cytotoxic type-1 cytokine pattern during age-dependent maturation of the immune response inversely correlates with CD30 cell expression and serum concentration. *Clin Exp Immunol* 117:291-7,1999
  45. Pizzolo G, Vinante F, Chilosi M. Biological prognostic factors in indolent lymphoma. *Haematologica (suppl)*

84:18-24,1999

46. Chilosi M, Doglioni C, Yan Z, Lestani M, Menestrina F, Sorio C, Benedetti A, Vinante F, Pizzolo G, Inghirami G. Differential expression of cyclin-dependent kinase 6 (CDK6, PLSTIRE) in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. *Am J Pathol* 152: 209-217,1998
47. Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, Krampera M, Zanolin E, Locatelli F, Gallati H, Chilosi M, Pizzolo G. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis. Correlation with clinical and biological features and outcome. *Br J Haematol* 102:1025-1034,1998
48. Pizzolo G, Vinante F, Nadali G, Krampera M, Morosato L, Chilosi M, Raiteri R, Sinicco A. High serum level of soluble CD30 in acute primary HIV-1 infection. *Clin Exp Immunol* 108:251-253,1997
49. Nadali G, Vinante F, Chilosi M, Pizzolo G. Soluble molecules as biological markers in Hodgkin's disease. *Leukemia & Lymphoma* 26 (suppl 1):99-106,1997
50. Fattovich G, Vinante F, Giustina G, Morosato L, Ruol A, Pizzolo G. Serum levels of soluble CD30 in chronic hepatitis type B: relation with virus replication and liver disease activity. *Clin Exp Immunol* 103: 105-110,1996.
51. Vinante F, Rigo A, Tecchio C, Patuzzo C, Ricetti MM, Morosato L, Cassatella M, Chilosi M, Pizzolo G. Preferential release of high amounts of interleukin-8 by myeloid blasts showing monocytic differentiation. *Haematologica* 81:195-200,1996.
52. Del Prete G, De Carli M, Almerigogna F, Daniel CK, D'Elis MM, Zancuoghi G, Vinante F, Pizzolo G, Romagnani S. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. *FASEB J* 9:81-86,1995.
53. Nadali G, Vinante F, Stein H, Todeschini G, Tecchio C, Morosato L, Chilosi M, Menestrina F, Kinney MC, Greer JP, Latza U, Perona G, Pizzolo G. Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large cell lymphoma. *J Clin Oncol* 13:1355-1360,1995.
54. Nadali G, Vinante F, Rigo A, Tecchio C, Morosato L, Zanolin E, Perona G, Chilosi M, Pizzolo G. Correlation between clinical features and circulating levels of the soluble form of ICAM-1 in Hodgkin's disease. *Int J Clin Lab Res* 25:84-87,1995.
55. Trentin L, Pizzolo G, Zambello R, Agostini C, Morosato L, Sancetta R, Adami F, Vinante F, Chilosi M, Gallati H, Semenzato G. Leukemic cells in hairy cell leukemia and B-cell chronic lymphocytic leukemia release soluble TNF receptors. *Leukemia* 9:1051-1055,1995.
56. Caligaris-Cappio F, Bertero MT, Converso M, Stacchini A, Vinante F, Romagnani S, Pizzolo G. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. *Clin Exp Rheumatol* 13:339-343,1995.
57. Pizzolo G, Vincenzi C, Vinante F, Nadali G, Janossy G. Ortho Permeafix™ fixation is not suitable for the flow cytometric detection of nuclear terminal transferase in acute myeloid leukemia-cells - reply. *Leukemia (letter)* 9:228, 1995.
58. Vinante F, Vassanelli A, Zanotti R, Nadali G, Krampera M, Vincenzi C, Morosato L, Chilosi M, Pizzolo G. Circulating levels of soluble CD23 molecule reflect clinical and biological features of leukemic B-cell chronic lymphocytic disorders. *Int J Clin Lab Res* 25:189-194,1995.
59. Pizzolo G, Vinante F, Nadali G, Chilosi M, Semenzato G. Circulating soluble ICAM-1 in patients with Hodgkin's disease. *Immunol Today (letter)* 15:140-141,1994.
60. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H, Pizzolo G. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. *J Clin Oncol* 12:793-797,1994.
61. Pizzolo G, Vincenzi C, Nadali G, Veneri D, Vinante F, Chilosi M, Basso G, Connelly MC, Janossy G. Detection of membrane and intracellular antigens by flow cytometry following ORTHO Permeafix™ fixation. *Leukemia* 8:672-676,1994.

62. Pizzolo G, Vinante F, Morosato L, Nadali GP, Chilosi M, Gandini G, Sinicco A, Raiteri R, Semenzato G, Stein H, Perona G. High serum levels of the soluble form of CD30 molecule in the early phase of HIV-1 infection as an independent predictor of progression to AIDS. *AIDS* 8:741-745,1994.
63. Pizzolo G, Rigo A, Vinante F, Chilosi M. Presence of interleukin-2 receptor  $\gamma$ -chain transcript in AML blasts. *Leukemia (letter)* 8:1597-1598,1994.
64. Manetti R, Annunziato F, Biagiotti R, Giudizi MG, Piccinni M-P, Giannarini L, Sampognaro S, Parronchi P, Vinante F, Pizzolo G, Maggi E, Romagnani S. CD30 expression by CD8<sup>+</sup> T cells producing Th2-type cytokines. Evidence for large numbers of CD8<sup>+</sup>/CD30<sup>+</sup> T cell clones in human immunodeficiency virus (HIV) infection. *J Exp Med* 180:2407-2411,1994.
65. Pizzolo G, Vinante F, Chilosi M, Romagnani S, Del Prete G. CD30 antigen and cellular biology of Reed-Sternberg cells. *Blood* 84:3983-3984,1994.
66. Vinante F, Morosato L, Siviero F, Nadali G, Rigo A, Veneri D, de Sabata D, Vincenzi C, Chilosi M, Semenzato G, Pizzolo G. Soluble forms of p55-IL-2Ra, CD8, and CD30 molecules as markers of lymphoid cell activation in infectious mononucleosis. *Haematologica* 79:413-419,1994.
67. Ambrosetti A, Nadali G, Vinante F, Ricetti MM, Todeschini G, Morosato L, de Sabata D, Bergamo Andreis IA, Chilosi M, Semenzato G, Pizzolo G. Soluble interleukin-2 receptor in hairy cell leukemia: A reliable marker of disease. *Int J Clin Lab Res* 23:34-37,1993.
68. Pizzolo G, Rigo A, Zanotti R, Vinante F, Vincenzi C, Cassatella M, Carra G, Castaman G, Chilosi M, Semenzato G, Zambello R, Trentin L, Libonati M, Perona G.  $\alpha$ (p55) and  $\beta$ (p75) chains of interleukin-2 receptor are expressed by AML blasts. *Leukemia* 7:418-425,1993.
69. Pizzolo G, Vinante F, Nadali G, Ricetti MM, Morosato L, Marrocchella R, Vincenzi C, Semenzato G, Chilosi M. ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. *Br J Haematol* 84:161-162,1993.
70. Ambrosetti A, Nadali G, Vinante F, Carlini S, Veneri D, Todeschini G, Morosato L, de Sabata D, Chilosi M, Maggi E, Parronchi P, Romagnani S, Semenzato G, Perona G, Pizzolo G. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease: relationship with clinical stage, tumor burden and treatment outcome. A longitudinal study. *Cancer* 72:201-206,1993.
71. Vinante F, Rigo A, Vincenzi C, Ricetti MM, Marrocchella R, Chilosi M, Cassatella MA, Bonazzi L, Pizzolo G. IL-8 mRNA expression and IL-8 production by acute myeloid leukemia cells. *Leukemia* 7:1552-1556,1993.
72. Pizzolo G, Vinante F, Rigo A, Chilosi M, Zanotti R, Semenzato G. Il recettore per l'interleuchina-2 sulle cellule normali e neoplastiche. *Haematologica (SI-6)* 78:8-12,1993.
73. Perona G, Ambrosetti A, Vinante F. Leucemie. In: "Crepaldi G, Trattato di Gerontologia e Geriatria", UTET editrice, Torino, pag 682-718,1993.
74. Pizzolo G, Vinante F, Morosato L, de Sabata D, Sinicco A, Raiteri R, Agostini C, Semenzato G. Determinants of HIV disease progression. *Lancet (letter)* 339:130,1992
75. Pizzolo G, Dallenbach F, Vinante F, Morosato L, de Sabata D, Ambrosetti A, Nadali G, Chilosi M, Semenzato G, Falini B, Josimovic-Alasevic O, Diamantstein T, Stein H. High serum levels of soluble interleukin-2 receptor and absence of detectable levels of soluble CD30 molecule: a specific diagnostic combination for hairy cell leukemia. *Leukemia & Lymphoma* 6: 385-388,1992.
76. Pizzolo G, Vincenzi C, Vinante F, Rigo A, Veneri D, Chilosi M, Dusi S, Poli G, Zambello R, Semenzato G, Berton G. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2-dependent cell proliferation in vitro. *Cell Immunol* 141:253-259,1992.
77. Vinante F, Pizzolo G, Rigo A, Vincenzi C, Sorio C, Cassatella M, Berton G. The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia. *Leukemia* 6:1257-1262,1992.
78. Pizzolo G, Ambrosetti A, Vinante F, Chilosi M, Semenzato G. Correlation between soluble interleukin-2

- receptor and neoplastic bulk in hairy cell leukemia. *Blood (letter)* 77:2540-2541,1991.
79. Agostini C, Pizzolo G, Zambello R, Trentin L, Siviero F, Vinante F, Morosato L, Francavilla E, Cadrobbi P, Semenzato G. Shedding of the soluble form of the CD8 complex by CD8+/HLA-DR+ cells in HIV-1-infected patients. *AIDS* 5:813-819, 1991.
  80. Trentin L, Zambello R, Pizzolo G, Vinante F, Ambrosetti A, Chisesi T, Vespignani M, Feruglio C, Adami F, Agostini C, Semenzato G. Tumor necrosis factor-alfa and B-cell growth factor induce leukemic hairy cells to proliferate in vitro. *Cancer Detect Prevent* 15:385-390,1991.
  81. Vinante F, Morosato L, De Sabata D, Pizzolo G. Soluble molecules in lymphoproliferative disorders. *Leukemia (suppl)* 5:18-21,1991.
  82. Todeschini G, Veneri D, Carlini D, Pizzolo G, Ambrosetti A, Bonesi R, Cassibba V, Vinante F, Meneghini V, Perona G. Ceftazidime and amikacin as empiric antibiotic therapy of febrile granulocytopenic patients with hematological malignancies. Report of 171 consecutive episodes. *Hematol Oncol* 9:137-146, 1991.
  83. Pizzolo G, Vinante F, Benedetti F, Vincenzi C, Morosato L, De Sabata D. L'immunofenotipo nelle leucemie. *Haematologica (suppl)* 76:19-25, 1991.
  84. Pizzolo G, Vinante F, Morosato L, De Sabata D, Sinicco A, Raiteri R, Agostini A, Semenzato G. Prognostic significance of soluble CD8 serum levels in HIV-1 infection. *AIDS (letter)* 6:133-134,1991.
  85. Ippoliti G, Vinante F, Rovati B, Di Franco L, Martinelli L, Viganò M, Pizzolo G. Serum levels of soluble interleukin-2 receptor (sIL-2R) fail to correlate with the occurrence and degree of rejection in heart transplant patients. *Clin Transplant* 4:1-4,1990.
  86. Pizzolo G, Vinante F, Chilosi M, Dallenbach F, Josimovic-Alasevic O, Diamantstein T, Stein H. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease. Relationship with disease activity and clinical stage. *Br J Haematol* 75:282-284,1990.
  87. Pizzolo G, Vinante F, Ambrosetti A, Chilosi M, Romagnani S, Diamantstein T, Stein H. Soluble molecules in lymphoproliferative diseases. In: *Immunological aspects of malignant lymphomas and cryoglobulinemia*, Ermes Milano, pages 91-102,1990.
  88. Pizzolo G, Stein H, Josimovic-Alasevic O, Vinante F, Zanotti R, Chilosi M, Feller AC, Diamantstein T. Increased serum levels of soluble IL-2 receptor, CD30 and CD8 molecules, and gamma-interferon in angioimmunoblastic lymphadenopathy. Possible pathogenetic role of immunoactivation mechanisms. *Br J Haematol* 75:485-488,1990.
  89. Vinante F, Pizzolo G. Le molecole solubili in oncoematologia. In: *Attualità in Ematologia*, S. Giovanni Rotondo, pag. 75-82,1990.
  90. Pizzolo G, Zanotti R, Vinante F, Vincenzi C, De Sabata D, Morosato L. Diagnosi immunofenotipica delle leucemie acute. In: "Atti dell'XI Corso di Aggiornamento in Ematologia", Pavia, pages 14-23,1990.
  91. Agostini C, Semenzato G, Vinante F, Sinicco A, Trentin L, Zambello R, Zuppini B, Zanotti R, Siviero F, Veneri D, Foà R, Pizzolo G. Increased levels of soluble CD8 molecule in the serum of patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. *Clin Immunol Immunopathol* 50:146-153, 1989.
  92. Chilosi M, Semenzato G, Vinante F, Menestrina F, Piazzola E, Focchiatti V, Sabbioni R, Zanotti R, Pizzolo G. Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic and phenotypic features. *Am J Clin Pathol* 92:186-191,1989.
  93. Trentin L, Pizzolo G, Feruglio C, Zambello R, Masciarelli M, Bulian P, Agostini C, Vinante F, Zanotti R, Semenzato G. Functional analysis of cytotoxic cells in patients with acute non-lymphoblastic leukemia in complete remission. *Cancer* 64:667-672,1989.
  94. Alberti A, Chemello L, Fattovich G, Pontisso P, Semenzato G, Colletta C, Vinante F, Pizzolo G. Serum levels of soluble interleukin 2 receptors in acute and chronic viral hepatitis. *Digest Dis Sci* 34:1559-1563,1989.
  95. Ambrosetti A, Semenzato G, Prior M, Chilosi M, Vinante F, Vincenzi C, Zanotti R, Trentin L, Portuese A,

- Menestrina F, Perona G, Agostini C, Todeschini G, Pizzolo G. Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk. *Br J Haematol* 73:181-186,1989.
96. Semenzato G, Siviero F, Vinante F, Zambello R, Trentin L, Agostini C, Zanotti R, Vincenzi C, Zuppini B, Chilosi M, Pizzolo G. Serum levels of soluble CD8 molecule are increased in patients with B chronic lymphocytic leukemia. *Eur J Cancer Clin Oncol* 25:1577-1581,1989.
  97. Zambello R, Pizzolo G, Trentin L, Agostini C, Chisesi T, Vinante F, Scarselli E, Zanotti R, Vespignani M, De Rossi G, Pandolfi F, Semenzato G. Evaluation of serum levels of soluble interleukin-2 receptor in patients with chronic lympho-proliferative disorders of T-lymphocytes. *Cancer* 64:2019-2023,1989.
  98. Pizzolo G, Trentin L, Vinante F, Agostini C, Zambello R, Masciarelli M, Feruglio C, Dazzi F, Todeschini G, Chilosi M, Veneri D, Zanotti R, Benedetti F, Perona G, Semenzato G. Natural killer cell function and lymphoid subpopulations in acute non-lymphoblastic leukaemia in complete remission. *Br J Cancer* 58:368-372, 1988.
  99. Semenzato G, Trentin L, Zambello R, Agostini C, Bulian P, Ambrosetti A, Vinante F, Prior M, Chilosi M, Pizzolo G. Origin of the soluble interleukin 2 receptor in the serum of patients with hairy cell leukemia. *Leukemia* 2:788-792,1988.
  100. Semenzato G, Bambara LM, Biasi D, Frigo A, Vinante F, Zuppini B, Trentin L, Feruglio C, Chilosi M, Pizzolo G. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. *J Clin Immunol* 8: 447-452,1988.
  101. Pizzolo G, Trentin L, Vinante F, Agostini C, Zambello R, Ranucci A, Luca M, Chilosi M, Dazzi F, Foà R, Caligaris-Cappio F, Perona G, Semenzato G. Rearrangement for T-cell receptor gene and co-expression of immature T-cell markers and natural killer cell phenotype, in a patient with acute lymphoblastic leukaemia. *Br J Haematol* 65:17-22,1987.
  102. Pizzolo G, Chilosi M, Vinante F, Dazzi F, Lestani M, Perona G, Benedetti F, Todeschini G, Vincenzi C, Trentin L, Semenzato G. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. *Br J Cancer* 55:427-428, 1987.
  103. Zanotti R, Castaman G, Vinante F, Fierro MT, Benedetti F, Meneghini V, Trentin L, Perona G, Chilosi M, Chisesi T, Semenzato G, Foà R, Pizzolo G. Il recettore solubile per l'IL-2 nelle leucemie acute. In: "Atti XXXI Congresso Nazionale SIE", Genova, Monduzzi Editore, Bologna, pages 841-844,1987.
  104. Prior M, Agostini C, Sinicco A, Vinante F, Martinelli G, Perona G, Battistella L, Foà R, Semenzato G, Pizzolo G. Aumento dei valori sierici del recettore solubile per l'IL-2 in corso di infezione da HIV: possibile significato clinico e biologico. In: "Atti XXXI Congresso Nazionale SIE", Genova, Monduzzi Editore, Bologna, pages 1053-1056,1987.
  105. Trentin L, Vinante F, Zambello R, Agostini C, Luca M, Pizzolo G, Semenzato G. Attività natural killer in pazienti con leucemia acuta non linfoblastica (LANL) in remissione completa: ruolo delle cellule aderenti. In: "Atti XXXI Congresso Nazionale SIE", Genova, Monduzzi Editore, Bologna, pages 825-830,1987.
  106. Vinante F, Trentin L, Zambello R, Agostini C, Luca M, Masciarelli M, Benedetti F, Perona G, Semenzato G, Pizzolo G. Studio immunologico delle popolazioni linfoidi normali nella leucemia acuta mieloide in remissione completa. Evidenze di un possibile controllo immunologico della ricaduta. In: "Atti XXXI Congresso Nazionale SIE", Genova, Monduzzi Editore, Bologna, pages 835-839,1987.
  107. Agostini C, Trentin L, Zambello R, Ambrosetti A, Vinante F, Chilosi M, Cetto G, Pizzolo G, Semenzato G. L'alfa interferone nei pazienti con Hairy Cell Leukemia attiva il sistema NK, ma non induce un'attività citotossica specifica verso le cellule hairy. In: "Atti XXXI Congresso Nazionale SIE", Genova, Monduzzi Editore, Bologna, pages 7-12,1987.
  108. Pizzolo G, Vinante F, Agostini C, Zambello R, Trentin L, Masciarelli M, Chilosi M, Benedetti F, Dazzi F, Todeschini G, De Rossi A, Semenzato G. Immunologic abnormalities in angio immunoblastic lymphadenopathy. *Cancer* 60:2412-2418, 1987.
  109. Chilosi M, Semenzato G, Cetto G, Ambrosetti A, Fiore-Donati L, Perona G, Berton G, Lestani M, Scarpa A, Agostini C, Trentin L, Zambello R, Masciarelli M, Dazzi F, Vinante F, Caligaris-Cappio F, Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of

- recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. *Blood* 70:1530-1535,1987.
110. Semenzato G, Cipriani A, Trentin L, Zambello R, Masciarelli M, Vinante F, Chilosi M, Pizzolo G. High serum levels of soluble interleukin-2 receptors in sarcoidosis. *Sarcoidosis* 4:25-27,1987.
  111. Pizzolo G, Vinante F, Sinicco A, Chilosi M, Agostini C, Perini A, Zuppini B, Semenzato G, Battistella L, Foà R. Increased levels of soluble interleukin-2 receptors in the serum of patients with human immunodeficiency virus infection. *Diagn Clin Immunol* 5:180-183,1987.
  112. Semenzato G, Foà R, Agostini C, Zambello R, Trentin L, Vinante F, Benedetti F, Chilosi M, Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. *Blood* 70:396-400,1987.
  113. Trentin L, Ambrosetti A, Zambello R, Agostini C, Masciarelli M, Vinante F, Chilosi M, Pizzolo G, Cetto G, Semenzato G. Alpha-interferon activated cytotoxic lymphocytes in hairy cell leukemia patients: evaluation of cytotoxic events. *Leukemia Res* 11:843-847,1987.
  114. Pizzolo G, Romagnani S, Vinante F, Agostini C, Benedetti F, Parronchi P, Maggi E, Sabbioni R, Chilosi M, Ambrosetti A, Semenzato G. Soluble interleukin-2 receptor in the serum of patients with Hodgkin's Disease: A new biological marker of disease activity. In: *Genotypic, Phenotypic and Functional Aspects of Haematopoiesis*, Grignani F, Martelli MF & Mason DY eds, Raven Press, pag. 211-214,1987.
  115. Pizzolo G, Lestani M, Vinante F, Chilosi M. Diagnostica differenziale immunoistologica nei linfomi non-Hodgkin. In: "XII Corso Nazionale di Aggiornamento in Ematologia Clinica", Società Ed Esculapio, Bologna, pag. 549-557,1987.
  116. Todeschini G, Vinante F, Veneri D, Benini F, Pasini F, Benedetti F, Zanotti R, Perona G. Progressi nel trattamento delle setticemie da *Pseudomonas* in soggetti neutropenici affetti da emopatie maligne. In: "Attualità in Ematologia", Monduzzi Editore, Bologna, pag. 721-724,1986.
  117. Pizzolo G, Vinante F, Dazzi F. I marcatori delle cellule linfoidi. In: "Prospettive degli anticorpi mono e policlonali nella diagnosi di laboratorio". Piovani Editore, Abano Terme, pag. 147-155,1986.
  118. Semenzato G, Pizzolo G, Agostini C, Ambrosetti A, Zambello R, Trentin L, Masciarelli M, Chilosi M, Vinante F, Perona G, Cetto G. Alfa-interferon activates the natural killer system in patients with hairy cell leukemia. *Blood* 68:293-296,1986.
  119. Pizzolo G, Vinante F, Benedetti F, Dazzi F, Semenzato G, Trentin L, Zambello R, Agostini C, Masciarelli M, Luca M, Todeschini G, Chilosi M, Perona G. Alterazioni quantitative, qualitative e funzionali delle sottopopolazioni linfoidi nella linfadenopatia angioimmunoblastica. In: "Attualità in Ematologia", Monduzzi Editore, Bologna, pag. 963-966,1986.
  120. Zanotti R, Ambrosetti A, Pizzolo G, Vinante F, Todeschini G, Chilosi M, Perona G. Leucemia linfatica cronica B "intermedia"; entità nosografica autonoma? In: "Attualità in Ematologia", Monduzzi Editore, Bologna, pag. 1031-1034,1986.
  121. Trentin L, Semenzato G, Pizzolo G, Agostini C, Zambello R, Chilosi M, Luca M, Risato R, Ambrosetti A, Vinante F, Prior M, Cetto G. Modificazioni immunologiche in tre pazienti con hairy cell leukaemia trattati con alfa interferone ricombinante. In: "Attualità in Ematologia", Monduzzi Editore, Bologna, pag. 509-513,1986.
  122. Pizzolo G, Chilosi M, Vinante F, Ambrosetti A, Todeschini G, Perini A, Lestani M, Perona G. Immunocitologia e immunoistologia delle cellule midollari normali e neoplastiche. *Haematologica* 70 (suppl):39-47,1985.
  123. Chilosi M, Pizzolo G, Caligaris-Cappio F, Ambrosetti A, Vinante F, Morittu L, Bonetti F, Fiore-Donati L, Janossy G. Immunohistochemical demonstration of follicular dendritic cells in bone marrow involvement of B-cell chronic lymphocytic leukemia. *Cancer* 56:328-332,1985.
  124. Todeschini G, Vinante F, Benini F, Perini A, Pasini F, Cetto G. Gram-negative septicemia in patients with hematologic malignancies. *Eur J Cancer Clin Oncol* 20:327-331,1984.



125. Todeschini G, Cetto G, Vinante F, Ambrosetti A, Benini F, Perona G. Monoterapia empirica con ceftazidime nelle infezioni di pazienti neutropenici affetti da emopatie maligne. Progressi in Chemioterapia, Giornale Italiano di Chemioterapia 3 (suppl 3):381-385,1983.
126. Cetto G, Todeschini G, Caramaschi G, Vinante F, Benini F, Perona G. Empiric therapy of infections in hematologic malignancies: a prospective randomized trial. Tumori 69:155-160,1983.

Verona, 5/30/2020  
Fabrizio Vinante